Financings in Brief: ChromaVision Medical Systems
This article was originally published in The Gray Sheet
ChromaVision Medical Systems: Nets approximately $29.2 mil. in initial public offering of 6.4 mil. common stock shares at $5 each completed Aug. 13. The issue commenced "when-issued" trading on the NASDAQ exchange under the symbol "CVSN" on July 2 and commenced "regular way" trading Aug. 8, the firm says. The IPO was accomplished via an offering of 6.4 mil. common stock share purchase rights to shareholders of information technology firm Safeguard Scientifics, which owns 37.4% of ChromaVision ("The Gray Sheet" July 14, p. 13)...
You may also be interested in...
Federal law requiring agencies to weigh and document potential environmental impacts of major regulatory actions does not dictate what happens next. Neither does it provide federal agencies with authorities beyond their statutory purviews, FDA/CDER leadership says.
The European Medicines Agency has reported progress with a collaborative project that involves other regulators in its assessments of COVID-19 products, and with the EU Medicines for All initiative for evaluating products for non-EU markets.
A potential decline in mRNA vaccine protection against the Delta variant is raising questions about the need for booster shots in the US. Ocugen Inc. and partner Bharat Biotech hope the changing dynamic of COVID-19 in the US will induce the FDA to reconsider additional clinical trial requirements for Covaxin, an inactivated whole virus vaccine authorized for emergency use in 16 countries.